The Conversation (0)
Eli Lilly (NYSE:LLY) and AstraZeneca (NYSE:AZN) are strengthening their immuno-oncology partnership.
Eli Lilly (NYSE:LLY) and AstraZeneca (NYSE:AZN) are strengthening their immuno-oncology partnership.
According to an article on Fierce Biotech:
Lilly [is] lining up a new series of combination studies matching its cancer therapies with AstraZeneca’s big PD-L1 program for durvalumab (MEDI4736).
Earlier this year Lilly ($LLY) and AstraZeneca ($AZN) agreed to combine durvalumab with Cyramza (ramucirumab). And that pact followed Lilly’s move to acquire AstraZeneca’s BACE inhibitor for Alzheimer’s with a $50 million upfront. Now a new lineup will add the following cancer programs for combination studies:
- Lilly’s TGF-beta kinase inhibitor galunisertib.
- A CXCR4 peptide antagonist.
- An anti-CSF-1R monoclonal antibody, to be combined with AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab.
- Lilly’s abemaciclib (a CDK4/6 inhibitors) will be added to Faslodex, AstraZeneca’s marketed selective estrogen receptor down regulator.
- Both Cyramza (ramucirumab) and necitumumab will be combined with AZD9291, AstraZeneca’s EGFR inhibitor.
As in their earlier cancer pact, the two pharma giants are keeping the financial terms secret.